Wednesday, December 3 | 8:40 a.m.-8:50 a.m. | W1-SSNMMI05-5 | S405
F-18 silicon-fluoride-acceptor (SiFA)-TATE (SiTATE) is a promising new PET radiotracer for imaging neuroendocrine tumors. Here, a study validates that imaging can be performed 60 minutes after patients are injected, a standard time frame for most tracers.
Currently, imaging with SITATE-PET/CT is performed 90 minutes after tracer injection, complicating its integration into settings in which most tracers are imaged 60 minutes after tracer injection.
Lukas Salvermoser, MD, of Ludwig Maximilian University Hospital in Munich, will present a study in which eight patients underwent F-18 SiTATE PET/CT 60, 90, and 120 minutes after injection. The analysis found no significant differences in tumor-to-background ratios across time points for the liver (p = 0.661), lymph nodes (p = 0.541), bone (p = 0.847), or overall lesion assessment (p = 0.725).
In addition, individual expert readers did not report any relevant qualitative visual difference between the time points, and all lesions could be clearly identified against the surrounding background.
“Early F-18 SiTATE-PET/CT at 60 minutes post-injection provides equivalent diagnostic performance to later imaging, enabling faster workflows and improved patient management without compromising accuracy,” Ebner and colleagues suggest.
Tune in to this Wednesday morning scientific session on neuroendocrine tumors to learn more.
